Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.4.0.3
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 31, 2015
Dec. 31, 2010
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Jul. 31, 2015
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue from transfer of intellectual property and other     $ 18,616,000 $ 12,529,000      
Deferred revenue     217,900,000   $ 232,900,000    
Grant repayment     0 25,889,000      
Pfizer | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Non-refundable and non-creditable upfront payment $ 295,000,000            
Revenue from transfer of intellectual property and other     17,700,000 $ 12,500,000      
Additional milestone payment to be received 275,000,000            
Deferred revenue     211,800,000        
Tesaro              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Additional milestone payment to be received   $ 30,000,000          
Upfront payment under license agreements   6,000,000          
Milestone payment received     20,000,000        
Additional milestone payment   85,000,000          
Milestone revenue recognized   $ 0          
Period from first commercial sale   12 years          
Merck | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Non-refundable and non-creditable upfront payment     23,000,000        
Additional milestone payment to be received     5,000,000        
Milestone payment received     18,500,000        
Amount payable each year     $ 5,000,000        
Period for yearly payment     4 years        
Intangible assets, estimated useful lives     13 years        
Accrued Expenses | Pfizer | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred revenue     $ 70,600,000        
Accrued Expenses | Merck | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payment received     4,900,000        
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred revenue     141,200,000        
Other Noncurrent Liabilities | Merck | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payment received     $ 13,600,000        
Minimum              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Intangible assets, estimated useful lives     3 years        
Minimum | Pfizer | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Each milestone payment 20,000,000            
Maximum              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Intangible assets, estimated useful lives     20 years        
Maximum | Pfizer | Collaborative Arrangement, Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Each milestone payment $ 90,000,000            
Pharmsynthez              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Ownership percentage     17.00%        
Rxi Pharmaceuticals Corporation              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Milestone payments             $ 50,000,000
Pharmsynthez Note Receivable | Notes | Pharmsynthez              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Debt face amount           $ 3,000,000.0